House bill boosts funding for AMR efforts and ID research but workforce needs remain unmet

The House FY 2027 Labor, Health and Human Services, Education and Related Agencies appropriations bill provides welcome increases for key ID programs, including the Centers for Disease Control and Prevention’s Antimicrobial Resistance Solutions Initiative and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. The bill also directs the Administration to brief the Appropriations Committee routinely on the status of all competitive and formula grants and Notices of Funding Opportunities, which enables important congressional oversight. However, the bill doesn’t include language on grant cancellations or payment management systems; language on both was included in the final FY 2026 bill.

While these investments are critical, the bill does not provide funding for the Bio-Preparedness Workforce Pilot Program, a bipartisan effort to close growing ID workforce. The bill also includes alarming cuts to HIV programs and global health, which are highlighted in a release from HIVMA.

As the FY 2027 appropriations process moves forward, and the Senate Appropriations committee is expected to consider its LHHS bill later this month, IDSA urges the Senate to provide deeper investments in ID programs, including the Bio-Preparedness Workforce Pilot Program, and work with the House to ensure robust funding for these programs is included in a final FY 2027 bill. We also call on the House and Senate to include language to help ensure grants for biomedical research and public health programs are disbursed in a fair and timely manner, according to Congressional intent in the final FY 2027 funding bill.

Additional details on the funding levels for specific agencies and programs in the appropriations bill are included below. 

FY 2027 House LHHS bill highlights

Top-line funding levels

• $111.9 billion for the Department of Health and Human Services, a decrease of $4.5 billion, or 4%, below the FY 2026 level
• $47.3 billion for the National Institutes of Health overall, a $100 million increase over FY 2026
• $8.1 billion for the Centers for Disease Control and Prevention overall, $1 billion below FY 2026
• The bill does not restructure any agencies.   

NIH

• $6.603.779 billion for NIAID, $18.5 million over FY 2026; AMR research is funded at $565 million, level funding
• $95.2 million for NIH’s Fogarty International Center, level funding

CDC

• $207 million for the Antimicrobial Solutions Initiative, a $10 million increase over FY 2026
• $58 million for the Advanced Molecular Detection program, a $15 million increase over FY 2026
• $24 million for the National Healthcare Safety Network, level funding with FY 2026
• $72.7 million for Travel and Port Health Protection, $15 million over FY 2026
• $184 million increase for readiness and emerging health threats
• $663.8 million for the Center for Global Health, $29 million below FY 2026; includes $293 million for Global Health Protection, level funding with FY 2026; consolidates Global HIV/AIDS, TB, Measles and Other Vaccine Preventable Diseases funding lines into a new Global Emerging Infectious Diseases grant
• Eliminates Domestic HIV/AIDS Prevention and Research, a $755.6 million cut; retains only the $220 million Ending the HIV Epidemic initiative
• Funds new Biothreat Radar program, which strengthens the nation’s early detection and response capacity for novel and high-consequence pathogens.
• $230 million for Public Health Data Modernization, an increase of $45 million above the FY 2026 level
• $370 million for Public Health Infrastructure and Capacity, an increase of $10 million above the FY 2026 level
• $35 million for the Infectious Diseases Rapid Response Reserve Fund, an increase of $10 million above the FY 2026 level 

Administration for Strategic Preparedness and Response

• $3.6 billion for ASPR in total funding, a decrease of $44 million below the FY 2026 level
• $3 million increase for ASPR’s National Special Pathogen System, which includes the National Emerging Special Pathogens Training and Education Centers and the 13 Regional Emerging Special Pathogen Treatment Centers

Health Resources and Services Administration 

• $2.3 billion for the Ryan White HIV/AIDS Program, a decrease of $225 million below the FY 2026 level (including elimination of funding for the Ending the HIV Epidemic initiative)
• $1.4 billion for HRSA Health Workforce Training, an increase of $25 million above the FY 2026 level 

Agency for Healthcare Research and Quality

• Eliminates funding for AHRQ

About IDSA
The Infectious Diseases Society of America is a global community of 13,000 clinicians, scientists and public health experts working together to solve humanity’s smallest and greatest challenges, from tiny microbes to global outbreaks. Rooted in science, committed to health equity and driven by curiosity, our compassionate and knowledgeable members safeguard the health of individuals, our communities and the world by advancing the treatment and prevention of infectious diseases. Visit idsociety.org to learn more.